The development of early ascites is associated with shorter overall survival in patients with hepatocellular carcinoma treated with drug-eluting embolic chemoembolization
Abstract Background A single-centre cohort study was performed to identify the independent factors associated with the overall survival (OS) of hepatocellular carcinoma (HCC) patients treated with transarterial chemoembolization with drug-eluting beads (DEB-TACE). Methods A total of 216 HCC patients...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2020-06-01
|
| Series: | BMC Gastroenterology |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s12876-020-01307-x |
| _version_ | 1818501896571191296 |
|---|---|
| author | María Pipa-Muñiz Susana Sanmartino Alicia Mesa Carmen Álvarez-Navascués Maria-Luisa González-Diéguez Valle Cadahía José-Eduardo Rodríguez Florentino Vega Manuel Rodríguez Serafin-Marcos Costilla-García María Varela |
| author_facet | María Pipa-Muñiz Susana Sanmartino Alicia Mesa Carmen Álvarez-Navascués Maria-Luisa González-Diéguez Valle Cadahía José-Eduardo Rodríguez Florentino Vega Manuel Rodríguez Serafin-Marcos Costilla-García María Varela |
| author_sort | María Pipa-Muñiz |
| collection | DOAJ |
| description | Abstract Background A single-centre cohort study was performed to identify the independent factors associated with the overall survival (OS) of hepatocellular carcinoma (HCC) patients treated with transarterial chemoembolization with drug-eluting beads (DEB-TACE). Methods A total of 216 HCC patients who underwent DEB-TACE from October 2008 to October 2015 at a tertiary hospital were consecutively recruited. The analysis of prognostic factors associated with overall survival after DEB-TACE, stressing the role of post-TACE events, was performed. Results The objective response (OR) rate (Modified Response Evaluation Criteria in Solid Tumors (mRECIST) criteria) to the first DEB-TACE (DEB-TACE-1) was 70.3%; the median OS from DEB-TACE-1 was 27 months (95% confidence interval (CI), 24–30). In the multivariate analysis, tumor size, AFP < 100 ng/mL and serum alkaline phosphatase were independent factors for survival following DEB-TACE-1. The most important clinical event associated with poor survival was the development of early ascites after DEB-TACE-1 (median OS, 17 months), which was closely related to the history of ascites, albumin and hemoglobin but not to tumour load or to response to therapy. Conclusions Early ascites post-DEB-TACE is associated with the survival of patients despite adequate liver function and the use of a supra-selective technical approach. History of ascites, albumin and hemoglobin are major determinants of the development of early ascites post-DEB-TACE. |
| first_indexed | 2024-12-10T21:02:35Z |
| format | Article |
| id | doaj.art-b4b435b91439426eb24373d97439b9c6 |
| institution | Directory Open Access Journal |
| issn | 1471-230X |
| language | English |
| last_indexed | 2024-12-10T21:02:35Z |
| publishDate | 2020-06-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Gastroenterology |
| spelling | doaj.art-b4b435b91439426eb24373d97439b9c62022-12-22T01:33:45ZengBMCBMC Gastroenterology1471-230X2020-06-0120111210.1186/s12876-020-01307-xThe development of early ascites is associated with shorter overall survival in patients with hepatocellular carcinoma treated with drug-eluting embolic chemoembolizationMaría Pipa-Muñiz0Susana Sanmartino1Alicia Mesa2Carmen Álvarez-Navascués3Maria-Luisa González-Diéguez4Valle Cadahía5José-Eduardo Rodríguez6Florentino Vega7Manuel Rodríguez8Serafin-Marcos Costilla-García9María Varela10Division of Gastroenterology and Hepatology, Hospital de CabueñesRadiology Department, Hospital Universitario Central de AsturiasRadiology Department, Hospital Universitario Central de AsturiasLiver Unit, Hospital Universitario Central de AsturiasLiver Unit, Hospital Universitario Central de AsturiasLiver Unit, Hospital Universitario Central de AsturiasRadiology Department, Hospital Universitario Central de AsturiasRadiology Department, Hospital Universitario Central de AsturiasLiver Unit, Hospital Universitario Central de AsturiasRadiology Department, Hospital Universitario Central de AsturiasLiver Unit, Hospital Universitario Central de AsturiasAbstract Background A single-centre cohort study was performed to identify the independent factors associated with the overall survival (OS) of hepatocellular carcinoma (HCC) patients treated with transarterial chemoembolization with drug-eluting beads (DEB-TACE). Methods A total of 216 HCC patients who underwent DEB-TACE from October 2008 to October 2015 at a tertiary hospital were consecutively recruited. The analysis of prognostic factors associated with overall survival after DEB-TACE, stressing the role of post-TACE events, was performed. Results The objective response (OR) rate (Modified Response Evaluation Criteria in Solid Tumors (mRECIST) criteria) to the first DEB-TACE (DEB-TACE-1) was 70.3%; the median OS from DEB-TACE-1 was 27 months (95% confidence interval (CI), 24–30). In the multivariate analysis, tumor size, AFP < 100 ng/mL and serum alkaline phosphatase were independent factors for survival following DEB-TACE-1. The most important clinical event associated with poor survival was the development of early ascites after DEB-TACE-1 (median OS, 17 months), which was closely related to the history of ascites, albumin and hemoglobin but not to tumour load or to response to therapy. Conclusions Early ascites post-DEB-TACE is associated with the survival of patients despite adequate liver function and the use of a supra-selective technical approach. History of ascites, albumin and hemoglobin are major determinants of the development of early ascites post-DEB-TACE.http://link.springer.com/article/10.1186/s12876-020-01307-xHepatocellular carcinomaDEB-TACEAscitesResponseSurvival |
| spellingShingle | María Pipa-Muñiz Susana Sanmartino Alicia Mesa Carmen Álvarez-Navascués Maria-Luisa González-Diéguez Valle Cadahía José-Eduardo Rodríguez Florentino Vega Manuel Rodríguez Serafin-Marcos Costilla-García María Varela The development of early ascites is associated with shorter overall survival in patients with hepatocellular carcinoma treated with drug-eluting embolic chemoembolization BMC Gastroenterology Hepatocellular carcinoma DEB-TACE Ascites Response Survival |
| title | The development of early ascites is associated with shorter overall survival in patients with hepatocellular carcinoma treated with drug-eluting embolic chemoembolization |
| title_full | The development of early ascites is associated with shorter overall survival in patients with hepatocellular carcinoma treated with drug-eluting embolic chemoembolization |
| title_fullStr | The development of early ascites is associated with shorter overall survival in patients with hepatocellular carcinoma treated with drug-eluting embolic chemoembolization |
| title_full_unstemmed | The development of early ascites is associated with shorter overall survival in patients with hepatocellular carcinoma treated with drug-eluting embolic chemoembolization |
| title_short | The development of early ascites is associated with shorter overall survival in patients with hepatocellular carcinoma treated with drug-eluting embolic chemoembolization |
| title_sort | development of early ascites is associated with shorter overall survival in patients with hepatocellular carcinoma treated with drug eluting embolic chemoembolization |
| topic | Hepatocellular carcinoma DEB-TACE Ascites Response Survival |
| url | http://link.springer.com/article/10.1186/s12876-020-01307-x |
| work_keys_str_mv | AT mariapipamuniz thedevelopmentofearlyascitesisassociatedwithshorteroverallsurvivalinpatientswithhepatocellularcarcinomatreatedwithdrugelutingembolicchemoembolization AT susanasanmartino thedevelopmentofearlyascitesisassociatedwithshorteroverallsurvivalinpatientswithhepatocellularcarcinomatreatedwithdrugelutingembolicchemoembolization AT aliciamesa thedevelopmentofearlyascitesisassociatedwithshorteroverallsurvivalinpatientswithhepatocellularcarcinomatreatedwithdrugelutingembolicchemoembolization AT carmenalvareznavascues thedevelopmentofearlyascitesisassociatedwithshorteroverallsurvivalinpatientswithhepatocellularcarcinomatreatedwithdrugelutingembolicchemoembolization AT marialuisagonzalezdieguez thedevelopmentofearlyascitesisassociatedwithshorteroverallsurvivalinpatientswithhepatocellularcarcinomatreatedwithdrugelutingembolicchemoembolization AT vallecadahia thedevelopmentofearlyascitesisassociatedwithshorteroverallsurvivalinpatientswithhepatocellularcarcinomatreatedwithdrugelutingembolicchemoembolization AT joseeduardorodriguez thedevelopmentofearlyascitesisassociatedwithshorteroverallsurvivalinpatientswithhepatocellularcarcinomatreatedwithdrugelutingembolicchemoembolization AT florentinovega thedevelopmentofearlyascitesisassociatedwithshorteroverallsurvivalinpatientswithhepatocellularcarcinomatreatedwithdrugelutingembolicchemoembolization AT manuelrodriguez thedevelopmentofearlyascitesisassociatedwithshorteroverallsurvivalinpatientswithhepatocellularcarcinomatreatedwithdrugelutingembolicchemoembolization AT serafinmarcoscostillagarcia thedevelopmentofearlyascitesisassociatedwithshorteroverallsurvivalinpatientswithhepatocellularcarcinomatreatedwithdrugelutingembolicchemoembolization AT mariavarela thedevelopmentofearlyascitesisassociatedwithshorteroverallsurvivalinpatientswithhepatocellularcarcinomatreatedwithdrugelutingembolicchemoembolization AT mariapipamuniz developmentofearlyascitesisassociatedwithshorteroverallsurvivalinpatientswithhepatocellularcarcinomatreatedwithdrugelutingembolicchemoembolization AT susanasanmartino developmentofearlyascitesisassociatedwithshorteroverallsurvivalinpatientswithhepatocellularcarcinomatreatedwithdrugelutingembolicchemoembolization AT aliciamesa developmentofearlyascitesisassociatedwithshorteroverallsurvivalinpatientswithhepatocellularcarcinomatreatedwithdrugelutingembolicchemoembolization AT carmenalvareznavascues developmentofearlyascitesisassociatedwithshorteroverallsurvivalinpatientswithhepatocellularcarcinomatreatedwithdrugelutingembolicchemoembolization AT marialuisagonzalezdieguez developmentofearlyascitesisassociatedwithshorteroverallsurvivalinpatientswithhepatocellularcarcinomatreatedwithdrugelutingembolicchemoembolization AT vallecadahia developmentofearlyascitesisassociatedwithshorteroverallsurvivalinpatientswithhepatocellularcarcinomatreatedwithdrugelutingembolicchemoembolization AT joseeduardorodriguez developmentofearlyascitesisassociatedwithshorteroverallsurvivalinpatientswithhepatocellularcarcinomatreatedwithdrugelutingembolicchemoembolization AT florentinovega developmentofearlyascitesisassociatedwithshorteroverallsurvivalinpatientswithhepatocellularcarcinomatreatedwithdrugelutingembolicchemoembolization AT manuelrodriguez developmentofearlyascitesisassociatedwithshorteroverallsurvivalinpatientswithhepatocellularcarcinomatreatedwithdrugelutingembolicchemoembolization AT serafinmarcoscostillagarcia developmentofearlyascitesisassociatedwithshorteroverallsurvivalinpatientswithhepatocellularcarcinomatreatedwithdrugelutingembolicchemoembolization AT mariavarela developmentofearlyascitesisassociatedwithshorteroverallsurvivalinpatientswithhepatocellularcarcinomatreatedwithdrugelutingembolicchemoembolization |